EAEbru Atasever Akkas

Ebru Atasever Akkas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ebru Atasever Akkas has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005)

    by Ertugrul Senturk, Petek Erpolat, Serra Kamer, Birsen Yücel, Büşra Şahin Barış, Pantea Bayatfard, Beste Atasoy, Hasan Oğuz Çetinayak, Ebru Atasever Akkaş, Papatya Bahar Baltalarlı, et al.

  • Open Access

    Real-world experiences in patients with Ewing sarcoma treated at a specialist centre in Turkey

    by Selma Çakmakcı, Neriman Sarı, Ebru Atasever Akkaş, Fatih Yıldız, Ebru Karakaya, Bektaş Kaya, Bedii Şafak Güngör, Ömür Berna Çakmak Öksüzoğlu, İnci Ergürhan İlhan


  • Open Access

    Factors Affecting Permanent Sensorineural Hearing Loss and Bone Conduction in Patients After Receiving Radiotherapy to the Head and Neck Region

    by Birsen YücEl, Eda Erdiş, Seher Bahar, Ebru Akkaş Atasever, Mustafa GürOl Celasun, Emine Elif Altuntaş

    This study aimed to investigate the factors affecting permanent sensorineural hearing loss (SNHL) and causing changes in bone conduction (BC) thresholds over time in patients after receiving radiotherapy (RT) or chemoradiotherapy (CRT) to the head and neck region. A total of 63 patients with irradiated HNC that were admitted to the Radiation Oncology Department between 2011 and 2018 were included in the study. All patients were assessed with pure tone audiometry at eight different time points (first before RT and last five years after completion of RT). A chi-square test was used to analyze the variables that affected permanent SNHL occurrence. Repeated measure analysis of variance was conducted to investigate the factors affecting change in the BC threshold at pure-tone average (0.5–2 kHz) and the air conduction (AC) threshold at 4 and 6 kHz frequencies over time. Median follow-up was 52 months (range, 12–110 months). SNHL was found in 18 (14%) of the 126 ears. According to the receiver operating characteristic analysis, the cut-off values of cochlear Dmean and Dmax radiation doses were 40 Gy [p=0.017, area under the curve (AUC): 0.676] and 45 Gy (p=0.008, AUC: 0.695). Dmean (≤40 Gy vs. >40 Gy) and Dmax (≤45 Gy vs. >45 Gy) cochlear doses and age (≤40 vs. >40 years) were determined as factors affecting SNHL in the chi-square test. Repeated measures showed that BC thresholds between 0.5–2 kHz and AC thresholds at 4 and 6 kHz increased over time. Age (≤40 vs. >40 years), treatment of head and neck cancer (RT vs. CRT), cisplatin use, and Dmean (≤40 Gy vs. >40 Gy) and Dmax cochlear dose (≤45 Gy vs. >45 Gy) were important factors affecting the course of BC threshold over time. Dmean and Dmax cochlear doses and age were found to be associated with permanent SNHL. Conduction thresholds worsened over time at all frequencies, and this trend was affected by cochlear doses, age, CRT, and cisplatin use.


  • Prognostic value of the systemic immune-inflammation index, systemic inflammation response index, and prognostic nutritional index in head and neck cancer

    by Ebru Atasever Akkas, Eda Erdis, Birsen Yucel

    Purpose This study sought to investigate the prognostic value of the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and prognostic nutritional index (PNI) in patients with head and neck cancer. Methods The data of 310 patients with head and neck cancer who were referred to the Radiation Oncology Clinic of Sivas Cumhuriyet University Faculty of Medicine (n = 271, 87%) and to S.B.U. Dr. Abdurrahman Yurtaslan Ankara Oncology Health Practice and Research Centre (n = 39, 13%) between January 2009 and March 2020 were retrospectively analysed. At the time of diagnosis, patients’ neutrophil, lymphocyte, monocyte, platelet and albumin levels were used to calculate their SII, SIRI and PNI indices. Results Multivariate analysis found the after variables to be independent prognostic factors for overall survival (OS): SII [hazard ratio (HR) 1.71, 95% confidence interval (CI) 1.18–2.47; p = 0.002] and PNI (HR 0.66, 95% CI 0.43–0.97; p = 0.038), stage (HR 2.11, 95% CI 1.07–4.16; p = 0.030), fraction technique (HR 0.49, 95% CI 0.28–0.85; p = 0.011) and age (HR 2.51, 95% CI 1.77–3.57; p = 0.001).The following variables were found to be independent prognostic factors for disease-free survival (DFS) in multivariate analysis: SII (HR 2.16, 95% CI 1.22–3.83; p = 0.008), fractionation technique (HR 0.17, 95% CI 0.004–0.64; p = 0.017) and age (HR 2.11, 95% CI 1.13–3.93; p = 0.019). Conclusion This study found a high SII to be an independent poor prognostic factor for both OS and DFS, while a low PNI was found to be an independent poor prognostic factor only for OS.


  • Open Access

    The relationship between systemic immune-inflammation indexes and treatment response in locally advanced esophageal cancer

    by Esra Keki̇lli̇, Ebru Atasever Akkaş, Serab Uyar, Emre Yekedüz

    Aim: Systemic immune-inflammation indexes have been reported to be associated with clinical outcomes in several malignancies. Herein, we aimed to evaluate the potential relationship between prognostic nutritional index (PNI), systemic immune-inflammation index (SII), the neutrophil- to- lymphocyte ratio (NLR), the monocyte- to- lymphocyte ratio (MLR), the platelet-to-lymphocyte ratio (PLR) and the treatment response in patients with esophageal cancer who underwent neoadjuvant chemoradiotherapy (CRT). Material and Method: Esophageal cancer (EC) patients who underwent neoadjuvant CRT were retrospectively enrolled in the study. Immune-inflammation indexes were calculated from pretreatment blood counts in samples obtained. The relationships between PNI, SII, NLR, MLR, PLR values, treatment response, and overall survival (OS) rates were examined. Results: The data of 103 patients with EC who were referred to the Radiation Oncology Clinic of Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital were retrospectively analyzed. In the univariate analysis for OS, alcohol consumption, CRT agent, NLR, MLR, PLR, SII and PNI were found as prognostic factors. Also alcohol consumption was found as an independent prognostic factor in multivariate analyzes (HR:5.201, 95% CI:1.9-14.2, p=0.01). Conclusion: In our study, high SII and low PNI values ​​were not found to be independent poor prognostic factors for OS, but lower OS rates were observed in patients with high SII and low PNI values.

  • Open Access

    Local control results in extremity soft tissue sarcomas

    by Gülçin Ertaş, Muzaffer Bedri Altundağ, Ebru Atasever Akkaş, Hayati Abanuz, Esra Keki̇lli̇, Fatih Göksel

    Aim: The aim of this study is to investigate local control results and effective predictive factors in local control of extremity soft tissue sarcomas, retrospectively. Material and Method: 51 patients underwent postoperative adjuvant radiotherapy (RT) in Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital between October 2008-January 2022. Patients who underwent post-operative adjuvant RT were treated with 60-68 Gy in 2 phases from 2 Gy /day using conformal radiotherapy technique. IMA chemotherapy protocol was applied to 31.4% of the patients after radiotherapy. Results: The median follow up time was 46 months range (1-135). Recurrence was detected in 5 of the patients and the mean time of recurrence was 11.6 months (min: 3-max: 27). 10 patients developed metastasis at follow-up, the mean time until metastasis was 27 months (min: 18- max: 46). The mean overall survival (OS) was 103 (min:4-max:139) months and the OS of 2, 5 and 10 years were 93%, 65% and 60%, respectively. Disease-free survival (DFS) was 97 (min:4-max:139) months; 2, 5 and 10 years of DFS were 77%, 65% and 60%, respectively. The OS in patients aged ≥65 years old was significantly lower than in patients <65 years old (p=0.02). Overall and disease-free survival was significantly lower in patients undergoing chemotherapy (p=0.037 for overall survival, p=0.013 for disease-free survival). The occurrence of recurrence, metastasis or death within 3 years after the operation was significantly higher than after 3 years (p<0.001). Local failure was significantly higher in grade 3 tumors (p=0.05). All patients who recurred had grade 3 tumors. Metastasis and excitus were significantly higher in the follow-up of patients who underwent chemotherapy at one point during their treatment (p=0.027 for metastasis, p=0.042). Conclusion: While favorable local control results are obtained with adjuvant high dose-conformal radiotherapy in extremity sarcomas, close follow up is important for distant metastasis and local recurrence, especially in the first 3 years.


    • 1 May 2021
      • Vol. 26  (3) , 698-706

    Long-term clinical outcome and dosimetric comparison of tandem and ring versus tandem and ovoids intracavitary application in cervical cancer

    by Ebru Atasever Akkas, Muzzafer Bedri Altundag

    Purpose: The two most common applicators used in the treatment of high dose rate (HDR) intracavitary brachytherapy (ICBT) are tandem and ovoid (TO) and tandem and ring (TR). We aimed to evaluate the relationship between these treatment plans with short and long-term clinical outcomes. Methods: This retrospective study included 50 patients who received a partial or complete response to external beam radiotherapy treatment (EBRT) and who were diagnosed with cervical cancer in our clinic between November 2015 and October 2019, including 25 TO patients and 25 TR patients. Left and right point A, high-risk clinical target volume (HRCTV) EQD2, D0.1cc, 1cc, 2cc for the bladder, rectum, sigmoid, upper, middle, and lower vagina doses were recorded and compared according to the applicator type using the dose-volume histogram (DVH) parameter calculated from 200 computed tomography (CT) databases. Results: Right point A dose EQD2, HR-CTVD90,95,98, D2cc rectum EQD2, upper vagina V7Gy, 10Gy, middle and lower vagina 0,1, 1, 2cc, upper vagina 5-mm lateral point dose and upper, middle, lower vagina average doses were all found to be significantly lower for TR than for TO (p<0.005). Conclusions: Although right point A dose EQD2, HRCTVD90,95,98 values were higher in TO than in TR, the rectum and vaginal doses also seemed more advantageous in TR. GUS and GIS toxicities, local control, distant metastasis, treatment responses and survival rates were similar in both the applicators, although vaginal toxicity was observed more in TO. Studies with a higher number of patients are warranted in the future.